Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Cancer
100%
Kidney Tumour
57%
Prostate Specific Membrane Antigen
47%
Fluorine-18
45%
Clear Cell Renal Cell Carcinoma
45%
Biopsy Technique
42%
Neoplasm
39%
Positron Emission Tomography
37%
Partial Nephrectomy
35%
Positron Emission Tomography-Computed Tomography
35%
Prostate Biopsy
27%
Prostatectomy
22%
Tumor
22%
Diseases
19%
Radioactive Tracer
18%
Methoxy Isobutyl Isonitrile Technetium Tc 99m
18%
Molecular Imaging
17%
Single Photon Emission Computed Tomography-Computed Tomography
16%
Radical Nephrectomy
16%
Magnetic Resonance Imaging
15%
Polyethylene Terephthalate
14%
Computer Assisted Tomography
14%
Risk Stratification
13%
Prostate Specific Antigen
13%
Overall Survival
10%
Inferior Vena Cava
10%
Health Care Cost
10%
Malignant Neoplasm
10%
Systematic Review
10%
Multiparametric Magnetic Resonance Imaging
10%
Retroperitoneal Lymph Node Dissection
9%
Tumor Thrombus
9%
Cancer
9%
Nephrectomy
9%
Recurrent Disease
9%
Bladder Cancer
9%
Circulating Tumor Cell
8%
Meta-Analysis
8%
Radiation Therapy
8%
Metastatic Carcinoma
8%
Pelvis
7%
Transitional Cell Carcinoma
7%
Conventional Imaging
7%
Biochemical Recurrence
7%
Surgeon
6%
Robot-Assisted Prostatectomy
6%
Kidney Function
6%
Cancer Specific Survival
6%
Biological Marker
6%
Cystectomy
6%
Keyphrases
Prostate Cancer
74%
Prostate-specific Membrane Antigen
60%
18F-DCFPyL
49%
Positron Emission Tomography/computed Tomography (PET/CT)
49%
Renal Cell Carcinoma
28%
Tumor
27%
Small Renal Mass
26%
Renal Mass
25%
Partial Nephrectomy
24%
Active Surveillance
21%
Radical Prostatectomy
20%
Molecular Imaging
20%
Radiotracer
19%
Reporting System
18%
99mTc-sestamibi
17%
Prostate Biopsy
17%
PET Imaging
17%
Metastatic Prostate Cancer
15%
Data Systems
15%
Transperineal Prostate Biopsy
15%
Multiparametric Magnetic Resonance Imaging (mpMRI)
14%
Oncological Outcomes
13%
Single-photon Emission Computed Tomography (SPECT)
13%
Radical Nephrectomy
13%
Prostate-specific Membrane Antigen Positron Emission Tomography
12%
Risk Stratification
12%
Renal Tumor
11%
95% Confidence Interval
10%
Positron Emission Tomography Imaging
10%
Aggressive Prostate Cancer
10%
Clear Cell Renal Cell Carcinoma (ccRCC)
10%
Tumor Thrombus
9%
Conventional Imaging
9%
SPECT-CT
9%
Meta-analysis
9%
Circulating Tumor Cells
8%
Renal Mass Biopsy
8%
Recurrent Prostate Cancer
8%
Overall Survival
8%
Metastatic Renal Cell Carcinoma (mRCC)
8%
Radiotracer Uptake
8%
Prostate-specific Antigen
8%
Bladder Cancer
8%
Robot-assisted Partial Nephrectomy
7%
Positron Emission tomography-CT
7%
Transperineal
7%
Patients with Prostate Cancer
7%
Delayed Intervention
7%
Oncocytoma
6%
Prostate-specific Antigen Level
6%